



# Clinical studies

CRISTAL<sup>®</sup>

MEDISOL<sup>®</sup>

Technoparc Epsilon 1  
300, rue Isaac Newton  
83700 SAINT-RAPHAËL  
FRANCE

+33 (0)4 94 45 83 75  
contact@deleo.fr  
[www.deleo-medical.com](http://www.deleo-medical.com)



EVALUATION OF TOLERABILITY AND EFFICACY OF THE CRISTAL  
CRYOLIPOLYSIS TREATMENT ON THE LOCALIZED FAT DEPOSITS IN  
OBESE SUBJECTS

Dr Thierry PASSERON, MD, PhD

## Clinical Study Report

### EVALUATION OF TOLERABILITY AND EFFICACY OF THE CRISTAL CRYOLIPOLYSIS TREATMENT ON THE LOCALIZED FAT DEPOSITS IN OBESE SUBJECTS

ID RCB 2015-A01285-44

Sponsor code NA

#### Sponsor

Mr. Frédéric SAMSON  
DELEO S.A.S  
Technoparc EPSILON  
300, rue Isaac Newton  
83700 St Raphaël  
FRANCE

#### Principal Investigator

Pr. Thierry PASSERON, MD, PhD  
Service de Dermatologie  
Hôpital L'Archet 2  
151, route de St Antoine de Ginestière  
BP3079, 06202 Nice Cedex 3  
FRANCE

Version number	Date
Final	25 April 2017

*This Study Report is the property of DELEO SAS and is a confidential document. It is not to be copied or distributed to other parties without written approval from DELEO SAS.*

## 1 TITLE PAGE

<b>Title of Study</b> EVALUATION OF TOLERABILITY AND EFFICACY OF THE CRISTAL CRYOLIPOLYSIS TREATMENT ON THE LOCALIZED FAT DEPOSITS IN OBESE SUBJECTS		
<b>Investigational Device</b> CRISTAL CRYOLIPOLYSIS	<b>Indication</b> Localized fat deposits in obese subjects	
<b>Study Design</b> Open study, monocentric, with intra-individual comparisons		
<b>Treatment Duration</b> 1 hour	<b>Dose</b> NA	<b>Subject Population</b> Twenty (20) obese subjects
<b>Sponsor Name</b> DELEO SAS	<b>Protocol Number</b>	<b>Clinical Phase</b> Medical device
<b>Study Initiation Date</b> ( <i>first subject enrolled</i> ) 14-Apr-2016	<b>Study Completion/Termination Date</b> ( <i>last subject completed</i> ) 05-Jul-2016	
<b>Sponsor Representative</b> ( <i>name and affiliation</i> ) Frederic SAMSON, CEO	<b>Principal Investigator</b> ( <i>name and affiliation</i> ) Pr. Thierry PASSERON, MD, PhD	
<b>Study Report Version</b> version #2	<b>Study Report Date</b> 25-April -2017	

This study was performed in compliance with Good Clinical Practice (GCP) including the archiving of essential study documents.

## 2 SYNOPSIS

<b>Name of Sponsor</b>	DELEO SAS
<b>Title of Study</b>	<b>EVALUATION OF TOLERABILITY AND EFFICACY OF THE CRISTAL CRYOLIPOLYSIS TREATMENT ON THE LOCALIZED FAT DEPOSITS IN OBESE SUBJECTS</b>
<b>Investigator(s)</b>	Pr. Thierry PASSERON, MD, PhD, Principal Investigator Dr. Abdallah KHEMIS, MD, Investigator Coordinator Pr. Jean Philippe LACOUR, MD, PhD, co-investigator Pr. Patrick FENICHEL, MD, co-Investigator
<b>Study Center(s)</b>	Dermatology Department Hôpital L'Archet 2 151, route de Saint Antoine de Ginestière 06202 Nice Cedex 3 France
<b>Publication(s)</b>	NA
<b>Study period</b> Date of First Enrollment: 15-Jul-2016 Date of Last Completed: 27-Sep-2016	<b>Phase of development</b> Medical Device
<p><b>Study Objectives</b></p> <p><b>Primary objective:</b></p> <ul style="list-style-type: none"> <li>- The primary objective of this trial was to reduce from at least 30% the greasy fold thickness after 2 months of the Cristal Cryolipolysis treatment using a caliper tool measurement.</li> </ul> <p><b>Secondary objective:</b></p> <ul style="list-style-type: none"> <li>- To assess the safety and tolerability of the Cristal Cryolipolysis treatment in the study</li> <li>- To assess the satisfaction of patient with regards to efficacy and tolerability of the treatment.</li> <li>- To assess the effects of LED light after Cristal Cryolipolysis treatment.</li> </ul>	
<p><b>Study Design</b></p> <p>Open study with intra-individual comparisons.</p> <p>The study consisted of a selection visit followed by three experimental visits (Day0, T1 month, T2month).</p>	
<p><b>Number of Subjects (planned and analyzed)</b></p> <p>Twenty (20) obese subjects</p>	

### **Diagnosis and Main Criteria for Inclusion**

- Adults, men and women ( $\geq 18$  to 65 years of age) with a BMI between 30 and 35.
- Greasy fold thickness between 2 -15 cm (measure performed by caliper)
- Stable weight without changes within the 6 months prior to the study and remaining stable during the study.

### **Test device description**

The Cryolipolysis Cristal is a class IIa medical device which consists to apply a controlled cooling on the fat deposits located on the body. Cooling is generated by an effect Peltier device.

The Cryolipolysis Cristal is dedicated to treat the located pocket of fat. It allows to improve the skin texture and significantly reduces the located fat layers. It is equipped with two handpieces allowing to treat simultaneously two areas.

This medical device is intended for doctor's offices; it has a EC marking following the 93/42/CEE directive.

### **Duration of Treatment**

1 hour

### **Study Efficacy Endpoints**

- **Primary Endpoint(s)**

Measure of the greasy fold thickness using the caliper at each visit

- **Secondary Endpoint(s)**

The secondary endpoints were the followings:

- Measure of the subcutaneous fat thickness by echography (at V2, V3 and V4)
- Measure of skin biomechanics (elasticity) using the Cutometer (at V2, V3 and V4)
- Measure of the target area using standardized photographs (at V2, V3 and V4)
- Measure of the glycaemia and lipids status at each visit.
- Measure of the patient satisfaction (at V3 and V4)

### **Principal Statistical Methods**

The principal criterion is the greasy fold thickness after 2 months of treatment. The comparison T2month versus baseline was performed using a Student t test for paired data.

The objective to obtain a reduction of at least 30% of the greasy fold thickness was checked by the calculation of the 95% interval of confidence of the mean reduction of the thickness at T2month. The reduction of 30% had to be comprised within this interval of confidence.

## Summary of Results

- **Subject Population**

Twenty obese subjects were included and completed the study. Most subjects were females (75%). At Screening, the mean age of the subjects was 45 years (from 28 to 65 years).

- **Efficacy Results**

- **Primary Endpoint(s)**

The greasy fold thickness decreased whatever the post-treatment with LED or not. Compared to the Screening visit, the greasy fold thickness was significantly reduced at T1month and T2month. The primary endpoint was reached at T2month because the expected percentage of 30% reduction was observed.

- **Secondary Endpoint(s)**

The subcutaneous fat thickness, measured by echography, decreased whatever the post-treatment with LED or not. Compared to the Before treatment value, the subcutaneous fat thickness was significantly reduced at T1month and T2month. At T2month, the reduction of subcutaneous fat thickness measured by echography was about -24%.

Concerning biomechanical properties of the skin, the results indicated that the Cristal Cryolipolysis procedure did not affect the skin firmness and even slightly improve the skin elasticity at T2month for both types of zones.

- **Safety Results**

Safety results showed a better tolerance on LED treated zone which displayed lower scores of erythema and edema following treatment procedure. Fifty-five percent (55%) of subjects did not feel any painful post-procedure reactions and the mean duration of pain was 5 days for subjects experiencing pain.

Concerning blood lipids, a decrease of blood cholesterol total, LDL and HDL was observed at T1month with normal level recovery at T2month. For the hormonal blood status, a decrease of Free T4 and an increase of Free T3 were measured at T1month with normal level recovery at T2month. No significant variations of TSH and no changes in glycaemia were measured during the study.

Two adverse events were reported. One AE concerned a pregnancy revealed by the pregnancy test of the last visit and was judged as non-related to the study content. The second AE was a severe local urticaria-like reaction observe just after the Cristal procedure (cold urticaria, AE related to treatment) and resolved within a few hours.

There was no sign of aggravation in patients with stretch marks.

## Conclusion

In the conditions of this study, the Cristal Cryolipolysis treatment was found efficient and safe to treat the subcutaneous fat deposits in obese patients.

## Date of Report

25 April 2017

# FAT REMOVAL USING NEW CRYOLIPOLYSIS DEVICE : A RETROSPECTIVE STUDY OF 418 PROCEDURES

Dr Michaël NAOURI

LETTER TO THE EDITOR

## Fat removal using a new cryolipolysis device: a retrospective study of 418 procedures

Editor

The selective effect of cold on the hypodermis is a well-known medical phenomenon.<sup>1,2</sup> Cryolipolysis<sup>3</sup> induces selective apoptosis of the adipocytes using controlled exposure to intense cold. Its safety and efficacy has been reported in several studies<sup>4,5</sup> but was recently challenged.<sup>6</sup>

A retrospective, observational, monocentric post-marketing study was conducted. A single session of cryolipolysis was evaluated on subjects who consulted for fat removal. Subjects were included consecutively and paid for their treatment. Patients

with medical history of cold disorders such as cryoglobulin or Raynaud's disease, visceral hernias, pregnancy, caesarean section within the last 6 months were excluded. The device used [Cristal™ cryolipolysis (Deleco, Saint Raphael, France)] benefits from the medical CE marking. It has two slightly curved handpieces that can be used simultaneously, with three different sizes. Thick protective epidermal membrane soaked with a cold-resistant gel was applied on the area. Cooling temperature was between -6 °C and -10 °C. Treatment duration was 60 min per area. A 5-min energetic massage was carried out immediately after treatment. A topical cream containing arnica extract (Cicabio Arnica<sup>®</sup>, Laboratoire Bioderma, Lyon, France) which reduces bruising was prescribed in order to limit and treat secondary ecchymosis caused by suction.

A total of 418 areas in 147 subjects underwent the procedure. Areas were: abdomen (144), anterolateral flank (156), inner thighs (48), back (26), underside of buttocks (26), inner knees

**Table 1** Treatment outcome

Efficacy	Location	N (patients)	Number of probes placed	Mean	Standard deviation	Minimum	Maximum	Median
Loss of perimeter (cm)	Abdomen	24	1	2.38*	1.69	0	6	2
	Thighs	3	1	1.33	0.58	1	2	1
	Knees	3	1	2.00	1.73	1	4	1
	Both flanks	8	2	2.13 <sup>†</sup>	2.36	0	7	2
	Under the Breasts	2	2	3.00	1.41	2	4	3
	Buttocks	2	2	4.50	4.95	1	8	4.5
	Both flanks + abdomen	15	3	4.00 <sup>*,†</sup>	2.36	2	10	3
Total loss of perimeter (cm)		57	-	2.79	2.15	0	10	2
Desire for a second session		57	Yes: 45 (80.36%) No: 11 (19.84%) Not specified: 1 (1.75%)					


\*CI at 95% for the difference in means: (0.173; 3.077).

t-test of the difference in means = 0 (and ≠): T-value = 2.32; P-value = 0.030; DL = 22.

<sup>†</sup>CI at 95% for the difference in means: (-0.34; 4.09).

t-test of the difference in means = 0 (and ≠): T-value = 1.82; P-value = 0.091; DL = 14.

Tolerance	Number of side-effects	Percentages per subject (%) (n = 147)	Percentages per area treated (%) (n = 418)
Pain making treatment impossible	1	0.68	0.24
Vasovagal attack	3	1.36	0.48
Painful induration after the session	4	2.72	0.96
Skin anaesthesia in the treatment area	1	0.68	0.24
Large bruising	2	1.36	0.48
Erythema and blistering	1	0.68	0.24
Total	12	7.48	2.63



**Figure 1** Up: just after treatment, down before (left) and 2 months after treatment (right)

(12) and breasts (6). One hundred and thirty-six (92.5%) subjects did not experience any adverse events. Two procedures could not be performed: one because of pain caused by lipedema,<sup>7</sup> the second because of a vasovagal attack with loss of consciousness 20 min after the probe was placed. Ten other subjects experienced unusual adverse events: vasovagal symptoms without loss of consciousness that did not interfere with treatment, painful induration after the session, skin anaesthesia in the treatment area, large bruising, erythema and blistering (Table 1). No serious or irreversible complication was reported.

Data from 57 area treated were reviewed for efficacy (Table 1, Fig 1). A statistically significant mean loss of circumference of 2.8 cm ( $P < 0.05$ ) was observed after the procedure including 1–3 handpieces. A loss of circumference of at least 1 cm was observed in 89.4% of patients; the maximum loss observed was 10 cm. A total of 75.4% of the patients were satisfied or very satisfied and 80.6% expressed their desire to make for a second session. It was a positive correlation between the subject's satisfaction and the objective decrease in circumference. There was no correlation between the subject's age or initial perimeter and the relative or absolute loss of circumference.

Our study allowed, evaluating objectively, the safety and efficacy of a new cryolipolysis device on a high number of

areas treated. The majority of adverse events observed were already reported.<sup>4</sup> One incidence of cold burning was reported. This was a superficial burn – erythema and blistering which healed rapidly. This incidence was caused by a membrane slipping and not because of the device malfunctioning. Overall, the frequency of this incidence (0.24%) was much lower than that for other energy-based devices, such as hair removal lasers or radio frequency.<sup>4</sup> No paradoxical adipose hyperplasia, considered being a much more serious adverse event, was reported.<sup>8</sup>

We made evaluations as objective as possible using anatomical markings and taking multiple measurements. The objective effect and level of subject satisfaction was very high. Since all subjects paid for their treatment, there was no gratitude bias.<sup>9</sup> Unfortunately, we failed in searching criteria statistically correlated with good answer to the procedure; age and initial parameters did not seem to influence treatment success.

Our study confirmed that the new cryolipolysis device Cristal (TM) is safe and effective to remove fat.

M. Naouri<sup>1,2,\*</sup>

<sup>1</sup>Centre Laser, Nogent sur Marne, France, <sup>2</sup>Centre Laser International de la Peau, Paris, France

\*Correspondence: M. Naouri. E-mail: michaelnaouri@yahoo.fr

## References

- 1 Vickers R. Equestrian cold panniculitis. *Br Med J* 1981; **282**: 405–431.
- 2 Epstein EH, Oren ME. Popsicle panniculitis. *N Engl J Med* 1970; **282**: 966–967.
- 3 Avram MM, Harry RS. Cryolipolysis for subcutaneous fat layer reduction. *Lasers Surg Med* 2009; **41**: 703–708.
- 4 Dierickx CC, Mazer JM, Sand M, Koenig S, Arigon V. Safety, tolerance, and patient satisfaction with noninvasive cryolipolysis. *Dermatol Surg* 2013; **39**: 1209–1216.
- 5 Mulholland RS, Paul MD, Chalfoun C. Noninvasive body contouring with radiofrequency, ultrasound, cryolipolysis, and low-level laser therapy. *Clin Plast Surg* 2011; **38**: 503–520.
- 6 Tremaine M, Avram MM. FDA MAUDE data on complications with lasers, light sources, and energy-based devices. *Lasers Surg Med* 2015; **47**: 133–140.
- 7 Naouri M, Samimi M, Atlan M *et al.* High-resolution cutaneous ultrasonography to differentiate lipoedema from lymphoedema. *Br J Dermatol* 2010; **163**: 296–301.
- 8 Singh SM, Geddes ERC, Boutrous SG, Galiano RD, Friedman PM. Paradoxical adipose hyperplasia secondary to cryolipolysis: an underreported entity? *Lasers Surg Med* 2015; **47**: 476–478.
- 9 Shek SY, Chan NPY, Chan HH. Non-invasive cryolipolysis for body contouring in Chinese—a first commercial experience. *Lasers Surg Med* 2012; **44**: 125–130.

DOI: 10.1111/jdv.13899

DIFFERENCE IN VISIBLE LIGHT-INDUCED PIGMENTATION ACCORDING  
TO WAVELENGTHS: A CLINICAL AND HISTOLOGICAL STUDY IN  
COMPARISON WITH UVB EXPOSURE

Dr Thierry PASSERON, MD, PhD

# Differences in visible light-induced pigmentation according to wavelengths: a clinical and histological study in comparison with UVB exposure

Luc Duteil<sup>1</sup>, Nathalie Cardot-Leccia<sup>2</sup>, Catherine Queille-Roussel<sup>1</sup>, Yves Maubert<sup>1</sup>, Yona Harmelin<sup>3</sup>, Fériel Boukari<sup>3</sup>, Damien Ambrosetti<sup>2</sup>, Jean-Philippe Lacour<sup>3</sup> and Thierry Passeron<sup>3,4</sup>

**1** Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), University hospital of Nice, Nice, France **2** Department of Pathology, University hospital of Nice, Nice, France **3** Department of Dermatology, University hospital of Nice, Nice, France **4** C3M, team 12, INSERM U1065, Nice, France

**CORRESPONDENCE** T. Passeron, e-mail: passeron@unice.fr

**KEYWORDS** pigmentation/UVB/visible light/p53/melanogenesis

**PUBLICATION DATA** Received 9 January 2014, revised and accepted for publication 20 May 2014, published online 2 June 2014

doi: 10.1111/pcmr.12273

## Summary

The visible light spectrum is wide, and it can be hypothesized that all the wavelengths between 400–700 nm do not induce the same photobiological effects on pigmentation. We assessed the potential pro-pigmenting effects of two single wavelengths located at both extremities of the visible spectrum: the blue/violet line ( $\lambda = 415$  nm) and the red line ( $\lambda = 630$  nm). We made colorimetric, clinical, and histological assessments with increasing doses of those lights on healthy volunteers. Then, we compared these irradiations to non-exposed and UVB-exposed skin. Colorimetric and clinical assessments showed a clear dose effect with the 415-nm irradiation, in both skin type III and IV subjects, whereas the 630 nm did not induce hyperpigmentation. When compared to UVB irradiation, the blue–violet light induced a significantly more pronounced hyperpigmentation that lasted up to 3 months. Histological examination showed a significant increase of keratinocyte necrosis and p53 with UVB, as compared to 415- and 630-nm exposures.

Until recent years, photodermatology studies were mainly focused on the ultraviolet (UV) domain of the electromagnetic spectrum which is known to have sufficient energy to produce biological effects in the skin (Svobodova et al., 2006). Because the damage induced by short UVA (320–340 nm) is similar to those of the UVB, the UVA domain was divided into UVA1 (340–400 nm) and UVA2 (320–340 nm) (Suh et al., 2007). Visible light (400–700 nm) was considered, until recently, as having no significant cutaneous photobiological effect other than

a thermal effect. Since the last two decades, the developments in the field of photodynamic therapy and various dermatological treatments using lasers and light-emitting diodes in the visible gave rise to numerous studies and to reconsider the cutaneous effects of visible light. In a recent study, the quality of the pigmentation observed after irradiation with UVA1 was compared with irradiation with visible light on skin type IV–VI subjects (Mahmoud et al., 2010). It was noted that the visible light induced pigmentation that lasted for the 2-week study

## Significance


This study demonstrates that various wavelengths of the visible part of solar spectrum have different effects on skin pigmentation. Although inducing a potent and long-lasting hyperpigmentation, the 415 nm light does not lead to a significant increase of p53, suggesting that other pathways are involved in this induced melanogenesis. The doses of blue–violet light that stimulate the pigmentation are achieved in less than 2 h of sun exposure, suggesting that the shorter wavelengths of visible light could play a key role in the worsening of some pigmentary disorders after sun exposure, despite the use of sunscreens with UVB and UVA protection.

period, whereas the pigmentation produced by UVA1 quickly faded during the study period. Neither pigmentation nor erythema was observed on one subgroup of skin type II subjects using the same experimental conditions. However, the visible light spectrum is wide, and it can be hypothesized that all the wavelengths between 400–700 nm do not induce the same photobiological effects on pigmentation. The *in vitro* data obtained, for example, on fibroblasts, clearly show that various wavelengths of the visible or the infrared can have opposite biological effects (Mcdaniel et al., 2010). Therefore, it is crucial to evaluate the photobiological effect of different wavelengths of the visible spectrum on pigmentation. We assessed in healthy subjects the potential pro-pigmenting effects of two single ‘pure’ wavelengths located at both extremities of the visible domain: the blue/violet line ( $\lambda = 415$  nm) that is potentially pro-pigmenting and the red line ( $\lambda = 630$  nm) that was shown active on proliferation and differentiation of melanocytes *in vitro* (Lan et al., 2006). To have the UV-induced pigmentation as reference, a UVB-exposed zone was also included in the study design.


In a first step, we determined the minimal pigmentary dose (MPD) for 415- and 630-nm irradiations. The colorimetry ITA angle that is inversely correlated with pigmentation (Del Bino and Bernerd, 2013) displayed a clear dose effect with the 415-nm irradiation (Figure 1A). When angle ITA is displayed for skin types separately, both sets of curves are similar but shifted by 20 ITA units

with lower values for skin type IV and higher for skin type III (Figure S1A, B). The pronounced decrease of ITA angle observed one hour after exposure is probably due to a mix between immediate pigmentation and erythema (which darkens the skin color). No effect on the ITA angle was observed with the 630-nm irradiation (Figure 1B and Figure S1C, D). A substantial IPD (immediate pigment darkening) was observed at 1 h after exposure to blue light, followed by a brown color hyperpigmentation that was maintained till the end of the study (Day 22) (Figure 1C). The pigmentation level was higher on skin type IV subjects compared with skin type III ones (Figure 1D–K). One hour after exposure, the pigmentation was accompanied by weak-to-moderate erythema. This erythema disappeared after 24 or 48 h, depending on the subjects. On the 630-nm exposed zones, no pigmentation and no erythema were observed whatever the time point is. Therefore, the MPD could not be determined on the 630-nm exposed zones, and the dose planned for the step 2 was fixed to 150 J/cm<sup>2</sup>. The MPD and MED values are summarized in Table S1 for both skin types.

In a second part of the study, new test zones were used for light combination evaluation (Figure S2) and were assessed at 24 h and 2 weeks after exposure. The evolution of ITA angle for combined skin type and for the different types of exposure is illustrated in Figure 2A. Statistical analyses allowed establishing the following ranking of exposure types on the induced pigmentation:



**Figure 1.** (A) Evolution of the ITA angle as a function of the 415-nm doses ( $n = 12$ ); (B) and 630-nm doses ( $n = 12$ ); (C) evolution of the clinical pigmentation score as a function of the 415-nm doses (for combined skin types,  $n = 12$ ). (D) Clinical example of pigmentation induced with increased doses of 415 nm light in skin type III subject 24 h after irradiation; (E) 7 days after irradiation; (F) 14 days after irradiation; (G) 21 days after irradiation; (H) in skin type IV subject 24 h after irradiation; (I) 7 days after irradiation; (J) 14 days after irradiation; (K) 21 days after irradiation.




**Figure 2.** (A) Evolution of ITA angle as a function of exposure types. If bars are associated with different letters, that means they are significantly different ( $P < 0.05$ ). For example, 24 h after exposure, control zone (a) is different from 100%R (b) and 70%R/30%B (b) which are not different. (B) Evolution of the pigmentation score as a function of exposure types and skin types. Clinical example of pigmentation after exposure (upper left, 70% blue and 30% red; upper right, non-exposed; lower left, UVB; lower right, 100% blue); (C) 24 h after irradiation; (D) after 1 week; (E) after 2 weeks. CTL, non-exposed zone; R, red light (630 nm); B, blue-violet light (415 nm).

- 1 A group containing the control zone, whose pigmentation is significantly lower than all others (excepted after week 1 where it is not different from R100%).
- 2 The group R100% and R70/B30%
- 3 The group R50/B50%, the UVB zone, and R30/B70%.
4. The group containing the zone B100% that is not always different from the previous group (in particular from the zone R30/B70%).

The evolution of clinical score of pigmentation as a function of types of exposure and skin types is illustrated in Figure 2B. The pigmentation score was somewhat higher for skin type IV compared with skin type III whatever the type of exposure is. On the other hand, as expected, the UVB-induced pigmentation was weak at 24 h after exposure, whereas all other light combinations induced higher levels of pigmentation. Overall, the higher levels of pigmentation score were produced by the B100% and the R30/B70%. Statistical comparisons, using combined or separated skin types, indicate that pigmentation score observed on the non-exposed control zone was always significantly lower than that measured on all exposed zones including the R100% one. Statistically, one and two weeks after exposure, the UVB-induced

pigmentation was not different from that of the B100%, the R30/B70% and R50/B50% scores. Erythema was observed 24 h after exposure with the highest scores for the UVB-exposed zone (mean  $\pm$  SD =  $1.4 \pm 0.7$ ), followed by the B100% ( $0.5 \pm 0.5$ ), the B70/R30% ( $0.1 \pm 0.2$ ) and the B50/R50% ( $0.04 \pm 0.1$ ). No erythema was observed on other test zones at 24 h and on all test zones at one week and two weeks after exposure. Histology results indicated that cellular damages were mainly produced by UVB exposure (higher keratinocyte necrosis, higher number of melanophages and higher p53 positivity in keratinocytes) and were significantly more important than those induced by B100% and other types of exposure (Figure 3 and Figure S4). No significant changes in melanin content can be found using Fontana–Masson staining. Using MITF staining, we did not observe significant difference in melanocyte number between control and UVB, blue or red irradiations at 24 h and 7 days, respectively (Figure S5). There was no difference either with the Ki67 labeling. The oxidative stress was assessed by the 8-oxoguanine labeling (Figure S3). It showed a mild-to-moderate positive mitochondrial staining concerning the basal keratinocytes and perivascular fibroblasts, at 24 h post-irradiation, and only for the UVB and the 630-nm



**Figure 3.** Histological analysis with hematoxylin and eosin staining and p53 staining at 24 h for control, 415-nm, 630-nm, and UVB irradiation.

conditions. Synthesis of histopathology and immunohistochemistry results is presented in Table S2.

Studies on light-induced skin pigmentation have focused mainly on the UV part of the solar spectrum. Up to now, very few studies have been carried out to study visible light effects on skin pigmentation (Kollias and Baqer, 1984; Mahmoud et al., 2010; Porges et al., 1988; Ramasubramaniam et al., 2011). In the previous studies, the spectral bands were fixed using optical filters. This process allowed eliminating a great proportion of UV light from the visible exposures, but due to the transmittance profile of the filters, traces of UV light, in particular UVA, could have been still present. Moreover, while it is now clearly demonstrated and accepted that UV A1, A2, B, and C induce significant different biological effects on the skin, most studies on visible light have used the entire visible part of the solar spectrum (Kollias and Baqer, 1984; Mahmoud et al., 2010; Porges et al., 1988; Ramasubramaniam et al., 2011). We show here for the first time that the blue/violet irradiation induces a dose-correlated hyperpigmentation, while the red line induces no or very slight modification of the pigmentation of the skin *in vivo*. Although red light was reported to enhance the melanocyte proliferation *in vitro* (Lan et al., 2006), our results show that it does not have significant effect on pigmentation *in vivo*, at least with physiological

doses, and the combination of red and blue light did not lead to a synergistic effect on pigmentation. These results support the fact that the wavelengths of the visible part of solar spectrum do not have similar biological properties in the skin, especially on pigmentation. As the hyperpigmentation was still highly pronounced 2 weeks after the 415-nm irradiation, we asked the subjects to come back after 3 months. Eleven subjects accepted to return. All of them still presented a marked hyperpigmentation on the area exposed to the blue–violet light (Figure S6). This blue light-induced pigmentation remained more pronounced than the UVB-induced hyperpigmentation (Figure S7). Interestingly, while 1.5 MED of UVB induces a significant necrosis of keratinocytes, and a strong increase in p53 expression, those effects were found significantly less pronounced with the blue–violet irradiation. When those histological markers were compared at doses inducing a comparative pigmentation (1.5 DEM for UVB and 50% dose of the 415 nm light), keratinocyte necrosis and p53 expression were almost absent and significantly lower as compared to those induced by UVB. Quite surprisingly, we did not observe any increase in 8-oxoguanine expression after one 415-nm irradiation at the doses used in this study. Although the evaluation of the oxidative stress is less accurate in tissue as compared to cultured cells, the 8-oxoguanine expression has been reported to be a good marker of this oxidative stress in the skin (Kunisada et al., 2005). It has been demonstrated that mitochondrial DNA (mtDNA) is a critical cellular target for ROS. Thus, ROS exposure leads to increased mitochondrial-generated ROS (Yakes and Van Houten, 1997), and mtDNA damage is a powerful marker of photoinduced skin aging (Birch-Machin et al., 2013; Tulah and Birch-Machin, 2013). Our results suggest that the oxidative stress should not play a significant role in the blue–violet light-induced hyperpigmentation. The p53 protein is known to play a key role in UVB-induced hyperpigmentation (Cui et al., 2007). As p53 appears to be significantly less induced after blue–violet irradiation, the hyperpigmentation observed should rely on other mechanisms. The biological pathway involved in this blue–violet light-induced hyperpigmentation warrants to be further studied as it could provide new therapeutic targets to prevent this visible light-induced hyperpigmentation. The mean solar intensity received at ground level is about  $1000 \text{ W/m}^2$  with a fraction of 44% of visible light (i.e.,  $440 \text{ W/m}^2$ ) (ASTM Standard, 2008). If we consider the visible spectrum from 400 to 700 nm, the blue–violet part represents about one-fifth of the visible energy and thus  $8.8 \text{ mW/cm}^2$ . Importantly, the 100% dose of blue–violet light used in this study was  $87.5 \text{ J/cm}^2$ , which corresponds to about 2 h and 45 min of sun exposure during summer. The 50% dose that induced similar pigmentation as 1.5 MED of UVB was  $43.8 \text{ J/cm}^2$ , which corresponds to 83 min of sun exposure. As a comparison, the 1.5 MED of UVB corresponded to 25 and 45 min of sun exposure during the peak of UVB emission for skin type III and skin type IV, respectively. Although the length

of sun exposure is higher to reach these doses for blue–violet light as compared to UVB, it remains clinically relevant. Many pigmentary disorders, and in first places melasma and post-inflammatory hyperpigmentation, worsen after sun exposure and especially in the summer period despite the use of sunscreens with a broad and efficient UVB and UVA protection. It might be hypothesized that the blue–violet part of the visible light could play a key role in this phenomenon. Using sunscreens effective against the entire visible light spectrum is almost impossible to use in daily practice. By showing that different wavelengths of the visible part of the solar spectrum have different effects on the skin pigmentation, our results suggest that it is probably not necessary to get a protection against the entire part of the visible light and that a tinted sunscreen providing a protection in the shorter wavelengths of the visible light could be helpful in those pigmentary disorders. These data open and foster new research avenue in the mechanisms involved in melanogenesis and in the prevention of pigmentary disorders.

## Acknowledgement

We thank Sandrine Destrée and Arnaud Borderie for technical help.

## Conflict of interest

This study was conducted with the technical and financial support of Deleo luminotherapy, St Raphael, France.

## References

- ASTM Standard G173 – 03, Standard tables for reference solar spectral irradiances (2008). Direct normal and hemispherical on 37° tilted surface, ASTM International, West Conshohocken, PA, 10.1520/G0173-03R08.
- Birch-Machin, M.A., Russell, E.V., and Latimer, J.A. (2013). Mitochondrial DNA damage as a biomarker for ultraviolet radiation exposure and oxidative stress. *Br. J. Dermatol.* *169*, 9–14.
- Cui, R., Widlund, H.R., Feige, E. et al. (2007). Central role of p53 in the suntan response and pathologic hyperpigmentation. *Cell* *128*, 853–864.
- Del Bino, S., and Bernerd, F. (2013). Variations in skin colour and the biological consequences of ultraviolet radiation exposure. *Br. J. Dermatol.* *169*(Suppl. 3), 33–40.
- Kollias, N., and Baqer, A. (1984). An experimental study of the changes in pigmentation in human skin in vivo with visible and near infrared light. *Photochem. Photobiol.* *39*, 651–659.
- Kunisada, M., Sakumi, K., Tominaga, Y., Budiyo, A., Ueda, M., Ichihashi, M., Nakabeppu, Y., and Nishigori, C. (2005). 8-Oxoguanine formation induced by chronic UVB exposure makes Ogg1 knockout mice susceptible to skin carcinogenesis. *Cancer Res.* *65*, 6006–6010.
- Lan, C.C., Wu, C.S., Chiou, M.H., Hsieh, P.C., and Yu, H.S. (2006). Low-energy helium-neon laser induces locomotion of the immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: recapitulation of vitiligo repigmentation in vitro. *J. Invest. Dermatol.* *126*, 2119–2126.
- Mahmoud, B.H., Ruvolo, E., Hessel, C.L., Liu, Y., Owen, M.R., Kollias, N., Lim, H.W., and Hamzavi, I.H. (2010). Impact of long-wavelength UVA and visible light on melanocompetent skin. *J. Invest. Dermatol.* *130*, 2092–2097.
- Mcdaniel, D.H., Weiss, R.A., Geronemus, R.G., Mazur, C., Wilson, S., and Weiss, M.A. (2010). Varying ratios of wavelengths in dual wavelength LED photomodulation alters gene expression profiles in human skin fibroblasts. *Lasers Surg. Med.* *42*, 540–545.
- Porges, S.B., Kaidbey, K.H., and Grove, G.I. (1988). Quantification of visible light-induced melanogenesis in human skin. *Photodermatology* *5*, 197–200.
- Ramasubramaniam, R., Roy, A., Sharma, B., and Nagalakshmi, S. (2011). Are there mechanistic differences between ultraviolet and visible radiation induced skin pigmentation? *Photochem. Photobiol. Sci.* *10*, 1887–1893.
- Suh, K.S., Roh, H.J., Choi, S.Y., Jeon, Y.S., Doh, K.S., Bae, J.H., and Kim, S.T. (2007). A long-term evaluation of erythema and pigmentation induced by ultraviolet radiations of different wavelengths. *Skin Res Technol* *13*, 360–368.
- Svobodova, A., Walterova, D., and Vostalova, J. (2006). Ultraviolet light induced alteration to the skin. *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* *150*, 25–38.
- Tulah, A.S., and Birch-Machin, M.A. (2013). Stressed out mitochondria: the role of mitochondria in ageing and cancer focussing on strategies and opportunities in human skin. *Mitochondrion* *13*, 444–453.
- Yakes, F.M., and Van Houten, B. (1997). Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress. *Proc. Natl Acad. Sci. USA* *94*, 514–519.

## Supporting information

Additional Supporting Information may be found in the online version of this article:

**Figure S1.** Evolution of the ITA angle as a function of the 415 nm doses [(A) for skin type III, n = 6; (B) for skin type IV, n = 6] and 630 nm doses [(C) for skin type III, n = 6; (D) for skin type IV, n = 6].

**Figure S2.** Test zones locations.

**Figure S3.** Immunohistochemical analysis for Oxo-8.

**Figure S4.** Immunohistochemical analysis for p53.

**Figure S5.** Immunohistochemical analysis for MITF.

**Figure S6.** Clinical example of pigmentation induced with increased doses of 415 nm light (10, 30, 60, 90, 110 and 150 J/cm<sup>2</sup>) in skin type IV subject, 3 months after one single irradiation.

**Figure S7.** Clinical example of pigmentation 3 months after exposure in skin type IV (upper left, 70% blue and 30% red; upper right, non-exposed; lower left, UVB; lower right, 100% blue)

**Data S1.** Methods.

**Table S1.** MED and MPD values as a function of skin types (mean ± SD).

**Table S2.** Synthesis of histology results.





Clinical studies

CRISTAL®

MEDISOL®

Technoparc Epsilon 1  
300, rue Isaac Newton  
83700 ST RAPHAËL

04 94 45 83 75  
contact@deleo.fr  
[www.deleo.fr](http://www.deleo.fr)